CANTICANTI home
Back to targets

Target detail

ABCC5

ATP binding cassette subfamily C member 5

Data: Live structured evidence (Supabase)

Marker index metadata

Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).

Display name: ATP binding cassette subfamily C member 5

Aliases: ABCC5, ATP binding cassette subfamily C member 5

Type / organism: protein_coding · Homo sapiens

Source: opentargets · ENSG00000114770

Index freshness: last_synced_at 2026-05-15T18:52:04.076+00:00 · updated 2026-05-15T18:52:04.575596+00:00

Disease hub (glioblastoma)Guided · ABCC5

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Target index (foundation)

This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.

Glioblastoma disease hub·Guided lookup
Live structured evidence · sources

Connectors represented in loaded rows for ABCC5. Empty groups mean no matching rows — not a claim about biology or clinical use.

  • Open TargetsLive when indexed

    Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).

  • ChEMBLLive when indexed

    Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).

  • CANTI signal builderLive when indexed

    Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.

Open Targets · disease–target evidence

Rows from disease_target_evidence for this symbol.

glioblastoma

literature · opentargets

ChEMBL · linked drugs (drug_targets)

Drug records tied via drug_targets — mechanistic linkage only.

FLOXURIDINE

chembl917

Open drug

PROSTAGLANDIN A1

chembl1084644

Open drug

DILAZEP

chembl126075

Open drug

CHEMBL2047886

chembl2047886

Open drug

CHEMBL2047885

chembl2047885

Open drug

CHEMBL2047884

chembl2047884

Open drug

TREQUINSIN

chembl285913

Open drug

DINOPROSTONE

chembl548

Open drug

CHEMBL1729458

chembl1729458

Open drug

RIFAMPIN

chembl374478

Open drug

CHEMBL1547456

chembl1547456

Open drug

ADEFOVIR

chembl484

Open drug

CHEMBL2047883

chembl2047883

Open drug

MERCAPTOPURINE ANHYDROUS

chembl1425

Open drug

ALPROSTADIL

chembl495

Open drug

2-ACETYLAMINOFLUORENE

chembl311469

Open drug

CHEMBL2047880

chembl2047880

Open drug

THROMBOXANE B2

chembl1552426

Open drug

DINOPROST

chembl815

Open drug

CISPLATIN

chembl11359

Open drug

PROBENECID

chembl897

Open drug

CYCLIC ADENOSINE MONOPHOSPHATE

chembl316966

Open drug

CHEMBL1871954

chembl1871954

Open drug

DIPYRIDAMOLE

chembl932

Open drug

CHEMBL1338248

chembl1338248

Open drug

CHEMBL2047881

chembl2047881

Open drug

ZAPRINAST

chembl28079

Open drug

SULFINPYRAZONE

chembl832

Open drug

CHEMBL2047882

chembl2047882

Open drug

CHEMBL395336

chembl395336

Open drug

MK-571

chembl15177

Open drug

SILDENAFIL

chembl192

Open drug

FLUOROURACIL

chembl185

Open drug

FLUORESCEIN DIACETATE

chembl1492044

Open drug
repoDB-style · approved-elsewhere discussion candidates

disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.

No matching rows

Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.

ClinicalTrials.gov · trial-matched options

Mirror rows whose text fields mention this symbol — registry context only.

No matching live evidence found

Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.

CANTI signal builder · target-linked research signals

Repurposing signal rows for drugs linked to this target via drug_targets.

Repurposing research signal · ALPROSTADIL · v0.1

Deterministic research signal for ALPROSTADIL. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

Open signals hub
Caution / negative-evidence rows

Structured rows with negative evidence_direction on disease–drug or signal tables.

No negative-direction rows

When structured evidence includes explicit negative direction fields, they surface here for oncology review.

Missing evidence · row counts by source string

No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).

  • chembl: 34
  • opentargets: 1
  • canti_signal_builder: 1
Summary row (aggregated list)

Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.

Disease contexts

0

Linked drugs

0

Linked in dataset

0

Research signals

0

Evidence badges (illustrative)

Doctor-discussion candidate and related tags are descriptive only.

Appears in source landscapeLinked in datasetRequires oncology review
Linked research signals (list read)

Signals list: Live structured evidence (Supabase)

Repurposing research signal · ALPROSTADIL · v0.1

Deterministic research signal for ALPROSTADIL. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.

View signals hub